Prolonged Clinical Follow-up of OPTIMA-5

Acute myocardial infarction (AMI) is one of the leading causes of death all over the world, and accounted for more than 100 thousand deaths in the US in 2019. Early PPCI reduces mortality in patients with STEMI. If PPCI cannot be performed within 120 minutes of presentation, guidelines recommend the use of thrombolytic therapy. However, it remains uncertain whether adjunctive thrombolytic therapy administered immediately prior to PPCI improves outcomes in patients undergoing the procedure within 120 minutes.

SAK is a fibrin specific fibrinolytic agent produced by Staphylococcus aureus that was first discovered in 1948. A recombinant form of SAK was approved by China Food and Drug Administration (CFDA) for treatment of patients with STEMI. It has been demonstrated that r-SAK is more potent than urokinase and recombinant streptokinase in rabbit models.

The OPTIMA-5 trial is an investigator-initiated, prospective, multi-center, randomized, patient blinded, controlled trial comparing a single bolus of half-dose r-SAK with NS in patients with STEMI presenting ≤12 hours of symptom onset and expected to undergo PPCI within 120 minutes. Between October 29, 2021 and August 14, 2022, 283 STEMI patients were screened in 8 centers in China and 200 were randomized to r-SAK group or control in a 1:1 ratio using a computer-generated randomization sequence.

On this basis, this study was aimed to conduct a 1-year follow-up study to further confirm the efficacy and safety of this novel reperfusion strategy for patients with STEMI.

Arm 1 and 2 inclusion and exclusion criteria

Inclusion criteria

• Age 18-75 years, weight ≥45 kg;
• Diagnosed as STEMI (meeting the following two criteria simultaneously):

i. Ischemic chest pain lasts ≥30 minutes; ii. Electrocardiogram indicates that ST-segment elevation ≥2 mm in 2 or more contiguous precordial leads or ≥1 mm in 2 or more peripheral leads;

• Time from onset of persistent chest pain to randomization <12 hours;
• Primary PCI expected to be performed within 120 minutes.

Exclusion criteria

• Cardiogenic shock;
• Active bleeding or at high risk of bleeding (including grade Ⅲ or Ⅳ retinopathy or retinal gastrointestinal or urinary tract hemorrhage within the past 1 month);
• Ischemic stroke or TIA in the past 6 months;
• History of hemorrhagic stroke;
• Platelet count <100×109/L or hemoglobin <100 g/L;
• Known intracranial aneurysm;
• Severe trauma, surgery or head injury within 1 month;
• Suspected aortic dissection or infective endocarditis;
• Recent puncture with difficult hemostasis by compression (eg, visceral biopsy, compartment puncture);
• Currently taking anticoagulants;
• Poorly controlled hypertension ( ≥180/110 mmHg);
• Hepatic or renal impairment (glutamic-pyruvic transaminase, glutamic oxalacetic transaminase, or γ -glutamyl transferase >2.5 times upper limit of normal value; creatinine >1.5 times upper limit of normal value);
• Known allergy to r-SAK;
• Pregnancy, lactation, or planning for pregnancy;
• History of myocardial infarction or CABG;
• Having taken antiplatelet drugs other than aspirin and ticagrelor, such as clopidogrel, prasugrel or cilostazol after the symptom onset;
• Patients with other conditions that made them unsuitable to be recruited at the discretion of the investigators.

Arm 3 inclusion and exclusion criteria Inclusion criteria

• Age ≥18, ≤75 years old, weight ≥45kg, gender is not limited；
• Taking maintenance dose of aspirin and ticagrelor for more than 3 days, or taking loading dose of aspirin (300mg) and ticagrelor (180mg);
• Inpatients with suspected coronary atherosclerotic heart disease scheduled for coronary angiography or interventional therapy.

Exclusion criteria

• Patients who had received r-SAK thrombolytic therapy before;
• Previous diagnosis of Staphylococcus aureus infection;
• Patients who were participating in other clinical trials;
• Other patients considered unsuitable for inclusion by the investigators.